Freshly Printed - allow 7 days lead
Couldn't load pickup availability
Collaborative Innovation in Drug Discovery
Strategies for Public and Private Partnerships
Rathnam Chaguturu (Edited by), R Chaguturu (Author), Ferid Murad (Foreword by)
9780470917374, Wiley
Hardback, published 8 August 2014
752 pages
24.4 x 16.5 x 3 cm, 1.175 kg
Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement. Dr. Chaguturu’s thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.
Foreword xv Preface xix About the Book xxv About the Editor xxvii Contributors xxix PART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1 1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT BETWEEN GOVERNMENT, INDUSTRY, AND UNIVERSITIES 3 2 DIVIDED WE FALL 11 3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN DRUG DISCOVERY 21 4 THE CHANGING FACE OF INNOVATION IN DRUG DISCOVERY 31 5 CURRENT TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIES TO DE-RISK 6 A PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERY AND FUTURE CHALLENGES 75 PART II: GOVERNMENTAL INITIATIVES ACCELERATE PRECOMPETITIVE COLLABORATION 85 7 THE VALUE OF UNIVERSITY–INDUSTRY PARTNERSHIPS 87 8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF TRANSLATIONAL RESEARCH APPROACHES 99 9 PARTNERSHIPS FOR DRUG REPOSITIONING: LESSONS FROM THE CTSA PHARMACEUTICAL ASSETS PORTAL 115 10 DEVELOPMENT PROGRAMS AT THE U.S. NATIONAL CANCER INSTITUTE: USE OF PUBLIC–PRIVATE PARTNERSHIPS AS A CATALYST TO ADVANCE CANCER THERAPY 135 11 NONINDUSTRIAL PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES: LESSONS FOR DRUG DISCOVERY PARTNERSHIPS WITH ACADEMIC AND GOVERNMENTAL INSTITUTIONS 159 12 DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TO DISCOVERY IMPASSE 173 PART III: A GAME CHANGER FOR AVERTING FUTURE PHARMA CLIFF 195 13 ACCELERATING INNOVATION IN THE BIOSCIENCE REVOLUTION 197 14 VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOUR PIPELINE 213 15 UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221 16 COLLABORATIVE INNOVATION IN PHARMACEUTICAL INDUSTRY: APPROACHES AND REQUIREMENTS 255 17 CLOSE CONTACT: A COLOCATION MODEL FOR ACADEMIC–INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267 18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA–INDUSTRY PARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THE BAYER–UNIVERSITY OF COLOGNE “PRIVILEGED PARTNERSHIP” 279 19 ACADEMIC, COMMERCIAL, AND BIODEFENSE CASE STUDIES FOR COLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING DRUG DISCOVERY 303 20 ACCESS PLATFORM: A STREAMLINED INTEGRATIVE PARTNERING PROCESS AT SANOFI TO COMMERCIALIZE UNIVERSITY-BASED INTELLECTUAL PROPERTY 319 21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP AND MEDIUM-SIZED BIOTECHNOLOGY COMPANIES 341 22 CHEMICAL CONSULTING 355 PART IV: NONPROFITS DRIVE BENCH-TO-BEDSIDE INNOVATION 367 23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369 24 THE MYELIN REPAIR FOUNDATION ACCELERATED RESEARCH COLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL RESEARCH 385 25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TO HUNTINGTON’S DISEASE 411 26 LESSONS FROM THE PAST AS A MEANS TO THE FUTURE: INSTITUT PASTEUR AS A MODEL STRATEGY 437 27 SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONAL COLLABORATIONS TO LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OF STRATEGIC PARTNERSHIP BETWEEN SANFORD-BURNHAM AND MAYO CLINIC 451 PART V: ACADEMIC SCREENING CENTERS COME OF AGE 487 28 FINDING THE MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THE ERA OF ACADEMIC SCREENING CENTERS 489 29 OPEN INNOVATION-BASED DRUG DISCOVERY IN EUROPE: SOME EXAMPLES OF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES INTEGRATING CHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499 30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT IS FLOURISHING 517 31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT FACILITIES TO STIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533 PART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 563 32 SUCCESSFUL TECHNOLOGY TRANSFER: LESSONS FROM THE TRANSLATIONAL MEDICINE RESEARCH COLLABORATION 565 33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING ACADEMIC DRUG DISCOVERIES 577 34 THE PIVOTAL ROLE OF THE ACADEMIC ENTREPRENEUR AND THE ENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE SCIENCES 609 PART VII: THE FINAL FRONTIER 621 35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVE TRANSLATIONAL SCIENCE AND PUBLIC–PRIVATE COLLABORATION 623 36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE INNOVATION IN BIOMEDICINE 653 37 THE COST OF TAKING EYES OFF THE TRUE END USER: FOCUS ON PATIENT NEEDS AND OUTCOMES 663 38 TO LEASH OR UNLEASH THE POWER OF PUBLIC–PRIVATE COLLABORATION: IN HEALTH AND DISEASE 679 Index 687
by Ferid Murad
If I have seen further it is by standing on the shoulders of giants.
—Isaac Newton
Wyatt R. Hume
William B. Mattes
James M. Shaeffer and Sarah MacDonald
Litao Zhang and Carl Decicco
PRECOMPETITIVE INITIATIVES 57
Anuradha Roy and Rathnam Chaguturu
Christopher A. Lipinski
Governments will always play a huge part in solving big problems. . . .
They also fund basic research, which is a crucial component of the innovation that improves life for everyone. —Bill Gates
Anthony M. Boccanfuso
Mark A. Scheideler
Kate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron M. Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, Peter G. Ruminski, Bruce E. Bloom, Pamela Nagasawa, and Betty P. Guo
Jason V. Cristofaro
John Watson
Bhushan Patwardhan
Coming together is a beginning, staying together is progress, and working together is success. —Henry Ford
Bernard H. Munos
Valentina Sartori, Michael Steinmann, Petra Jantzer, and Matthias Evers
Assem S. el Baghdady and Yasser M.S. el Baghdady
Monika Lessl and Khusru Asadullah
Peter A. Covitz and Terrence D. Ruddy
Stefan Herzig, Marion Rozowski, and Ingo Flamme
Barry A. Bunin and Sean Ekins
Paul R. Eynott and Carole Fages
Allen B. Reitz and Kathleen M. Czupich
Lester A. Mitscher
Can’t afford to innovate? Open up! —Henry Chesbrough
Tonny Johnson and Sanchayita Kar
Gali Hagel
Allan J. Tobin
Spencer L. Shorte
Thomas D.Y. Chung, Sundeep Khosla, Andrew D. Badley, and Michael R. Jackson
Open access high-throughput drug discovery in the public domain is a Mount Everest in the making. —Rathnam Chaguturu
Nathan S. Blow
Philip Gribbon
Horst Flotow and Alex Matter
David Camp
Everything that can be invented has been invented. —Charles Duell
Assem S. el Baghdady
Christopher Paschall
Donna Marie De Carolis
No one can whistle a symphony; it takes a whole orchestra to play it.
—Halford E. Luccock
Ibis Sánchez-Serrano
Elizabeth Iorns
Deborah E. Collyar
Hakim Djaballah
Subject Areas: Chemistry [PN]
